Terry Sharpe
Dermatology · Stockbridge, GANPI 1285784439
Payments from drug & device makers
Across 549 payments — averaging $44.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10K
- Galderma Laboratories, L.p.$3K
- Journey Medical Corporation$2K
- Regeneron Healthcare Solutions, Inc.$2K
- UCB, Inc.$1K
- AbbVie$989
- plus $7K from 26 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- LEO Pharma AS$500
What the payments were for
- Consulting fees$3,45014%
- Speaking & faculty fees$5,44522%
- Travel & lodging$3,74415%
- Food & beverage$11,16446%
- Education$4912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 52 | $9,971 |
| Galderma Laboratories, L.p. | 26 | $2,506 |
| Journey Medical Corporation | 4 | $1,575 |
| Regeneron Healthcare Solutions, Inc. | 66 | $1,566 |
| UCB, Inc. | 89 | $1,079 |
| AbbVie | 47 | $989 |
| Dermavant Sciences, Inc. | 25 | $893 |
| Organon | 21 | $860 |
| Sanofi | 42 | $811 |
| Arcutis Biotherapeutics, Inc. | 31 | $798 |
| Johnson & Johnson | 45 | $795 |
| Incyte Corporation | 17 | $412 |
| Novartis | 14 | $406 |
| Sun Pharmaceutical Industries Inc. | 12 | $254 |
| Mayne Pharma Commercial LLC | 12 | $253 |
| Amgen | 8 | $208 |
| Lilly USA, LLC | 8 | $178 |
| E.r. Squibb & Sons, L.L.C. | 5 | $143 |
| Sanofi-aventis U.S. LLC | 1 | $70 |
| LEO Pharma Inc. | 3 | $70 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $70 |
| Almirall LLC | 3 | $69 |
| ANI Pharmaceuticals, Inc. | 2 | $55 |
| Fidia Pharma USA Inc. | 2 | $43 |
| Taro Pharmaceuticals USA, Inc. | 2 | $41 |
| Kyowa Kirin, Inc. | 2 | $39 |
| Bristol Myers Squibb | 2 | $39 |
| Verrica Pharmaceuticals Inc. | 1 | $32 |
| Phadia US Inc. | 1 | $21 |
| Dermira, Inc. | 1 | $19 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Botanix SB Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,294 in reported general payments places this provider in the 85th percentile of 345 dermatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 22 | $290,653 |
| Dupixent PenDupilumab | 69 | $255,672 |
| RinvoqUpadacitinib | 11 | $68,771 |
| Dupixent SyringeDupilumab | 13 | $49,699 |
| Doxycycline Ir-DrDoxycycline Monohydrate | 46 | $22,352 |
| SeysaraSarecycline Hcl | 19 | $19,531 |
| ZoryveRoflumilast | 16 | $13,849 |
| OraceaDoxycycline Monohydrate | 13 | $11,068 |
| Pimecrolimus | 35 | $10,715 |
| Ivermectin | 27 | $8,719 |
| Fluorouracil | 21 | $7,318 |
| Tacrolimus | 40 | $5,558 |
| FinaceaAzelaic Acid | 12 | $5,075 |
| Clocortolone Pivalate | 22 | $4,928 |
| Desoximetasone | 71 | $3,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $795 | $290,65322 claims |
| AbbVieRinvoq | $989 | $68,77111 claims |
| Almirall LLCSeysara | $69 | $19,53119 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $798 | $13,84916 claims |
| Galderma Laboratories, L.p.Oracea | $2,506 | $11,06813 claims |
| LEO Pharma Inc.Finacea | $70 | $5,07512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 345 dermatology providers in Georgia.
Other dermatology in Stockbridge
- David CohenMacon$5.5M
- Jamie WeismanAtlanta$4.9M
- Tiffani HamiltonAlpharetta$3.3M
- Firas HougeirDouglasville$3.3M
- Jonathan WeissSnellville$2.4M
- Mark KnautzPowder Springs$1.7M
- Gerald SlagelFayetteville$1.2M
- Zakiya RiceAtlanta$1.1M
- Corinne HowingtonSavannah$874K
- Alia BrownSnellville$838K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.